Create a presentation outline with the following details: Topic: Sglt2 inhibitors Target Audience: Doctors Length: 15 Slides Other Instructions: Make it uptodate with latest trials and guidelines. Last slide may have humor if appropriate
Reading File
Searching PubMed
SGLT2 inhibitors cardiovascular renal outcomes
Searching the Web
SGLT2 inhibitors latest guidelines 2025 2026 cardiovascular heart failure renal
Finding Sources
Searching PubMed
SGLT2 inhibitors heart failure hospitalized acute
Searching PubMed
SGLT2 inhibitors new indications atrial fibrillation sleep apnea liver
Reading File
Reading File
Searching PubMed
SGLT2 inhibitors emerging indications MASH obesity atrial fibrillation
Finding Sources
Searching PubMed
SGLT2 inhibitors adverse effects safety DKA genital infections
Searching the Web
SGLT2 inhibitors 2025 2026 new FDA approvals indications obesity MASH atrial fibrillation
Reading File
Reading File
Reading File
Running Command
Writing File
Running Command
The presentation was built successfully. Here's your download link:
SGLT2 Inhibitors 2026
Presentation · PPTX
What's Inside – All 15 Slides
| # | Slide Title | Key Content |
|---|---|---|
| 1 | Title Slide | Bold dark theme with 3 headline stats (3+ indications, 60% HHF reduction, 35% renal risk reduction) |
| 2 | Agenda | Numbered 15-topic roadmap |
| 3 | Class Overview | Table: Empagliflozin, Dapagliflozin, Canagliflozin, Ertugliflozin, Sotagliflozin – indications by drug |
| 4 | Mechanism of Action | PCT glucose reabsorption, osmotic diuresis, + 6 pleiotropic effects |
| 5 | Landmark Trials | 10-trial table: EMPA-REG, CANVAS, DECLARE, DAPA-HF, EMPEROR-Reduced/Preserved, CREDENCE, DAPA-CKD, EMPA-KIDNEY, SOLOIST-WHF |
| 6 | Cardiovascular Benefits | 4 visual cards: 11% ↓ MACE, 15% ↓ CV death, 31% ↓ HHF, 13% ↓ all-cause death (meta-analysis data) |
| 7 | Heart Failure – All EF | HFrEF vs. HFpEF columns; 2025 in-hospital initiation data (DAPA ACT HF-TIMI 68) |
| 8 | Renal Protection | CREDENCE/DAPA-CKD/EMPA-KIDNEY stats; JAMA Jan 2026 meta-analysis; KDIGO 2024 & ADA 2025 thresholds |
| 9 | Glycemic & Metabolic Effects | HbA1c, weight, BP, uric acid effects; insulin-independent mechanism |
| 10 | Safety Profile | 6 cards: genital infections, UTI, volume depletion, euglycemic DKA, amputation (canagliflozin signal), Fournier's gangrene |
| 11 | Dosing & Contraindications | Dosing table with eGFR thresholds; perioperative sick-day rules |
| 12 | 2024–2026 Updates | JAMA 2026, Circulation 2025 (in-hospital HF), Circulation 2024 (GLP-1+SGLT2), generic dapagliflozin, emerging frontiers |
| 13 | GLP-1 + SGLT2 Combination | 3-column comparison; additive CV + renal benefit from Neuen et al. 2024 |
| 14 | Guidelines & Prescribing Pearls | ADA 2025, ACC/AHA/HFSA 2022, KDIGO 2024 summary boxes |
| 15 | Takeaway + Humor | 5 key bullets + cardiologist/endocrinologist/nephrologist joke about generic prescribing |
Design: Navy/teal/yellow palette, dark title and content slides, data-forward tables and cards, no generic clipart.
This is a shared conversation. Sign in to Orris to start your own chat.